Genitourinary Cancers

A clinical scenario of renal cell carcinoma treated with surgery and adjuvant pembrolizumab is reviewed by a panel of experts.

Drs Barata and Ornstein describe how they treat certain subgroups of patients with advanced RCC, particularly those with brain or bone metastases.

7.Dr Ornstein explains how he selects between IO-TKI and IO-IO therapy in the first-line setting in advanced RCC.

A review of the first-line IO/TKI combination regimens available for advanced RCC and the factors considered in choosing an appropriate treatment.

Arnab Basu, MD, presents the patient profile of a 58-year-old woman with advanced renal cell carcinoma presenting with gross hematuria.

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the phase 3 PROBE trial in advanced renal cell carcinoma.

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

Expert perspectives on lenvatinib/pembrolizumab combination therapy in renal cell carcinoma, including appropriate dosing and adverse event management.

Shared insight on the patient and disease factors that inform the selection of therapy for favorable-risk renal cell carcinoma.

Dr Bilen discusses factors to consider when choosing a first-line therapy for advanced clear-cell RCC

David Braun, MD, delves into data from the CheckMate 214 trial that focused on ipilimumab with nivolumab.

Dr Sumeet Bhatia highlights the challenges faced by community oncologists who treat patients with advanced renal cell carcinoma and which patients they refer to academic centers.

Two oncologists describe common adverse events seen with IO-IO combination treatment regimens for advanced renal cell carcinoma, and how they interpret quality of life data from the CheckMate 214 trial.

A second clinical scenario focusing on favorable-risk renal cell carcinoma managed with lenvatinib-pembrolizumab therapy.

A brief discussion on triplet therapy being investigated in patients with intermediate- and poor-risk renal cell carcinoma.

Moshe C. Ornstein, MD, MA, explains the results from the CheckMate 9ER trial that studied cabozantinib with nivolumab.

Pedro C. Barata, MD, MSc, reviews the data from the KEYNOTE-426 trial, which focused on axitinib with pembrolizumab.

Toni K. Choueiri, MD, discusses follow-up data from the pivotal phase 3 KEYNOTE-564 examining adjuvant pembrolizumab in patients with clear cell RCC and additional areas that are ripe for further research.

Philippe E. Spiess, MD, MS, FACS, discusses the rationale for investigating the MTAP pathway in genitourinary cancers.

Experts discuss how to treat advanced renal cell carcinoma with brain metastases and when to refer patients to an academic center.

Treating a patient with advanced renal cell carcinoma with ipilimumab-nivolumab based on data from the CheckMate 214 trial.

Focusing on immunotherapy in the setting of intermediate- and poor-risk renal cell carcinoma, panelists review toxicity management and duration of response.

Experts review a clinical scenario of intermediate- and poor-risk renal cell carcinoma that is managed with ipilimumab-nivolumab and nivolumab maintenance.

Mehmet A. Bilen, MD, discusses the CLEAR trial that looked at lenvatinib with pembrolizumab as first-line therapy for RCC.

Tian Zhang, MD, provides an overview of renal cell carcinoma (RCC).